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Lipoprotein(a) is a predictor for cardiovascular mortality
of hemodialysis patients
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Lipoprotein(a) is a predictor for cardiovascular mortality of tionship between increased Lp(a) and the cardiovascular
hemodialysis patients. mortality in Japanese HD patients.
Background. Although hemodialysis (HD) patients have
been associated with elevations in serum lipoprotein(a) [Lp(a)]
levels, relatively little has been published on the link between METHODS
Lp(a) and the risk for atherosclerotic cardiovascular death in
Serum Lp(a) was measured simultaneously in all pa-HD patients.
Methods. Lipoprotein(a) was measured in 390 HD patients. tients treated in our dialysis unit as of November, 1995.
The relationship between Lp(a) and mortality (overall and The subjects were 390 patients on HD [241 men and 149
cardiovascular) was determined during 28 months of prospec- women, 333 nondiabetes mellitus (non-DM) and 57 DM]
tive follow-up.
and 105 normal controls. The patients’ mean age wasResults. Hemodialysis patients demonstrated Lp(a) concen-
56.6 6 14.1 (sd) years old, and the mean HD durationtrations that were approximately two times as high as that of
healthy controls (median, 16 vs. 8 mg/dl, P , 0.001; mean, 22.9 was 10.1 6 7.5 years (range 0.3 to 30.0). Serum Lp(a)
vs. 12.1 mg/dl, P , 0.01). Lp(a) showed a significant correlation was measured by latex-enhanced turbidimetric assay and
between albumin, total cholesterol, low-density lipoprotein albumin by bromocresol green. The subjects were di-
cholesterol, and C-reactive protein. The high-Lp(a) group
vided into two groups according to the 75th percentile[Lp(a) $ 30 mg/dl] showed significantly higher mortality than
Lp(a) value (30 mg/dl), comprising the high-Lp(a) groupthe low-Lp(a) group [Lp(a) , 30 mg/dl] in a Kaplan–Meier
(mean 50.2 mg/dl, N 5 98) and the low-Lp(a) groupsurvival analysis (P , 0.05). Multiple logistic regression analysis
demonstrated albumin, age, and diabetic state as significant (mean 13.1 mg/dl, N 5 292). The age of the high- and
risk factors for overall death. However, if confined to athero- low-Lp(a) groups was 58.5 6 13.4 vs. 55.9 6 14.3 years
sclerotic cardiovascular death, Lp(a) (P , 0.01), age, and dia- old (P 5 NS), and the albumin concentration was 3.8 6betic state were the only independent contributors.
0.5 vs. 4.0 6 0.4 (P , 0.05). The relationship betweenConclusions. Lp(a) is an independent risk factor for athero-
Lp(a) and death of presumed atherosclerotic origin wassclerotic cardiovascular death in Japanese patients receiving
chronic dialysis therapy. determined during 28 months of follow-up. The cause
of death was ascertained by chart review. Statistical eval-
uation was performed with simple regression, chi-square
test, unpaired Student’s t-test, Mann–Whitney’s U-test,Dyslipidemia is common in end-stage renal disease
and multiple logistic regression analysis, which allows(ESRD) patients and is associated with increased mortal-
for adjustment of confounders. Covariates included inity. Lipoprotein(a) [Lp(a)] is a genetically determined
multiple logistic regression analysis were age, gender,risk factor for vascular disease and has a potential link
albumin, Lp(a), and diabetic state. C-reactive proteinbetween coagulation and the development of atheroscle-
was excluded because it has a significant correlation withrosis [1–4]. Its levels vary markedly among ethnic groups
both albumin and Lp(a). Calculations were performedand several pathological conditions [5–8]. Elevated
using the SPSSt for Windows (version 7.5) statisticalLp(a) in hemodialysis (HD) patients has been reported
software. P values of less than 0.05 were considered[2–4, 6], but its role in the development of vascular com-
statistically significant.plications or atherosclerotic death has yet to be fully
proven. This study was designed to determine the rela-
RESULTS
A cross-sectional analysis of serum Lp(a) demon-Key words: albumin, atherosclerosis, cardiovascular disease, dyslipide-
mia, end-stage renal disease. strated a skewed distribution with a median value of 16
mg/dl (range 1.0 to 147) in HD patients and with 8 mg/dl 1999 by the International Society of Nephrology
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Fig. 1. Kaplan-Meier statistical analysis. Per-
cent survival over 28 months in 390 patients
stratified by Lp(a) $ 30 mg/dl (dashed line)
vs. , 30 mg/dl (solid line). P , 0.05.
(range 0.1 to 56.0) in normal controls. No significant
differences in Lp(a) levels were found in diabetic state
and gender groups. Serum Lp(a) was positively corre-
lated with total cholesterol, low-density lipoprotein cho-
lesterol, and C-reactive protein and was inversely corre-
lated with serum albumin (r 5 20.149, P , 0.01). No
correlation was evident between Lp(a) levels and the
patient’s age or duration on HD. Forty-nine patients
died during the observation period, and 18 of them
(36.7%) were due to atherosclerotic cardiovascular
causes—8 in the high-Lp(a) group and 10 in the low-
Lp(a) group. Cardiovascular death included three acute
myocardial infarctions, seven strokes, three sudden
deaths, and five other atherosclerotic causes. The high-
Lp(a) group showed a significantly higher mortality than
the low-Lp(a) group in the Kaplan–Meier survival analy-
Fig. 2. Relative risk for death in relation to overall and atheroscleroticsis (P , 0.05; Fig. 1). However, albumin concentration
causes. Adjustments were made for age, diabetic state, and albumin
in high-Lp(a) group was significantly lower than the low- concentration (N 5 390). High Lp(a): $ 30 mg/dl; low Lp(a): , 30 mg/dl.
Lp(a) group. Using a multiple logistic regression model,
independent predictors for overall mortality were albu-
min (P , 0.05), age (P , 0.001), and diabetic state (P ,
mains to be established. Only a small number of articles0.001). In contrast to this, independent predictors for
have been published showing that Lp(a) has a relation-atherosclerotic cardiovascular death were only Lp(a)
ship to a cardiovascular event [2, 3] or blood access(P , 0.01), age (P , 0.001), and diabetic state (P ,
occlusion [4]. The result of this prospective study demon-0.05). Cardiovascular death risk in patients with Lp(a)
strated the clear association between high Lp(a) and30 mg/dl and over was 3.9 times higher than patients
cardiovascular mortality in a large number of cases (N 5with Lp(a) less than 30 mg/dl when adjusted for albumin,
390). The pathogenesis of atherosclerosis due to highage, and diabetic state (Fig. 2). Each year of age in-
Lp(a) includes interference with fibrinolytic cascade andcreased the cardiovascular death risk by 1.07 times,
promotion of smooth muscle cell proliferation by reduc-whereas DM increased it 3.4 times compared with non-
ing the activation of transforming growth factor-b viaDM patients.
plasminogen inhibition [9]. Lp(a) levels are genetically
determined and differ considerably among ethnic groups
DISCUSSION [1]. This study suggests that that Lp(a) could be an ath-
erosclerotic risk factor in Japanese patients on HD.The importance of Lp(a) as a risk factor for an athero-
sclerotic death in patients with chronic renal failure re- Although Lp(a) levels are predominantly genetic con-
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